It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Nico Chen has given his Buy rating due to a combination of factors including Amgen’s consistent performance in launching blockbuster drugs and positive clinical trial data, as well as strategic ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

Amgen Inc.'s stock took a hit Monday after the biotechnology giant lost a bull, amid concerns that prices already reflect investor optimism over the obesity drug candidate, leaving more downside ...

Strategic acquisitions and pipeline expansions remain central to future growth plans. Amgen revealed a positive third quarter of 2024, exceeding earnings expectations. Despite some challenges in ...

Restaurant Brands Asia , the India franchisee of Burger King, reported a wider second-quarter loss on Monday, as ...

Across the recent three months, 11 analysts have shared their insights on Amgen AMGN, expressing a variety of opinions spanning from bullish to bearish. The following table summarizes their recent ...

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their ...

Even single day's delay in deciding bail plea adversely affects fundamental rights of citizens: SC NEW DELHI: Deprecating the practice of courts keeping bail applications pending for years, the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...